Microcap Ledger TriSalus Life Sciences, Inc. $TLSI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Westminster, CO
- Fiscal year end
- December 31
- Shares outstanding
- 61,574,600 [10-Q 2026-08-06]
What the company doesAI summary of filing
TriSalus Life Sciences is a clinical-stage medical device and biopharmaceutical company. The company develops TriNav, a medical device that is currently generating revenue from consignment orders to customers, and nelitolimod, a drug candidate in clinical development for which the company has not yet received marketing approval from any regulatory authority. TriSalus does not currently have internal manufacturing capability and relies on third-party contractors for supply and manufacturing of both its device and drug candidates. The company generates revenue from existing customers but generally lacks long-term contractual commitments and faces significant regulatory, manufacturing, and commercialization challenges ahead. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $20.31M | −$7.65M | −$16.61M | $46.29M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $45.15M | −$39.23M | −$18.01M | $20.44M | [10-K 2026-03-05] |
| FY ended Dec 2024 | $29.43M | −$30.05M | −$40.84M | $8.53M | [10-K 2026-03-05] |
- Quarterly cash burn
- −$8.30M
- Cash runway Estimate
- ~16.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 30,493,137 | [10-Q 2024-11-14] |
| 2025-03-31 | 32,272,462 | [10-K/A 2025-05-30] |
| 2025-05-09 | 37,838,962 | [10-Q 2025-05-15] |
| 2025-08-06 | 49,867,279 | [10-Q 2025-08-12] |
| 2025-11-10 | 49,964,311 | [10-Q 2025-11-13] |
| 2026-03-02 | 61,306,437 | [10-K 2026-03-05] |
| 2026-05-08 | 61,416,535 | [10-Q 2026-05-12] |
| 2026-08-04 | 61,574,600 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-11-13; declared effective 2025-12-04 [S-3 2025-11-13]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-05 | Cox Bryan F. | sell | 296 | $4.39 | [4 2026-10-07] |
| 2026-10-05 | Marshak Richard | sell | 325 | $4.39 | [4 2026-10-07] |
| 2026-10-05 | Stevens Jennifer | sell | 316 | $4.39 | [4 2026-10-07] |
| 2026-10-05 | Szela Mary T | other | 2,693 | $4.38 | [4 2026-10-07] |
| 2026-07-01 | Patience David | other | 14,650 | $4.46 | [4 2026-07-06] |
| 2026-06-30 | Szela Mary T | grant | 3,990 | $3.87 | [4 2026-07-01] |
| 2026-06-30 | Marshak Richard | grant | 561 | $3.87 | [4 2026-07-01] |
| 2026-06-29 | Marshall Richard Henry | grant | 60,000 | — | [4 2026-06-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-22 | 8-K | Other events |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-07 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-20 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 8-K | Shareholder vote results |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-05-12 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-04-29 | 8-K | Director or officer change |
| 2026-04-07 | 8-K | Director or officer change; Regulation FD disclosure |
Alerts for $TLSI
Email me when TriSalus Life Sciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.